Heartbeam Shares Rise 43% After FDA Decision, Top Stocks Moving Premarket

Heartbeam shares surged 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its 12-lead Electrocardiogram Synthesis Software. The company is pursuing multiple options, including an appeal process or a 510(k) resubmission. Other stocks moving in pre-market trading include SMX, Zenta Group, and Tilray Brands, which declined 15% after announcing a 1-for-10 reverse stock split.